Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 8, 1998, Pages 719-731

  Ladner, Christopher J ^a   Lee, John M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARECOLINE; BETHANECHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; METRIFONATE; MILAMELINE; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; PIRENZEPINE; PLACEBO; RIVASTIGMINE; TACRINE; TROPICAMIDE; XANOMELINE;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPHARMACOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0031821608     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199808000-00001     Document Type: Review

References (122)

1. Earnest RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-64
2. Terry RD, Katzman R. Senile dementia of the Alzheimer type. Ann Neurol 1983;14:497-506
3. Botwinick J, Storandt M, Berg L. A longitudinal, behavioral study of senile dementia of the Alzheimer type. Arch Neurol 1986;43: 1124-27
4. Petry S, Cummings JL, Hill MA, Shapira J. Personality alterations in dementia of the Alzheimer type. Arch Neurol 1988;45:1187-90
5. Knopman DS, Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol 1989;46:141-45
6. Woodruf-Pak DS, Finkbiner RG, Sasse DK. Eyeblink conditioning discriminates Alzheimer's patients from non-demented aged. Neuroreport 1990;1:45-48
7. Liu L, Gauthier L, Gauthier S. Spatial disorientations in persons with early senile dementia of the Alzheimer type. Ame J Occup Ther 1991;45:67-74
8. Hyman BT, Van Hoesen GW, Damasio AR. Memory-related neural systems in Alzheimer's disease: An anatomic study. Neurology 1990;40:1721-30
9. Benzing, WC, Mufson, EJ, Armstrong, DM. Immunocytochemical distribution of peptidergic and cholinergic fibers in the human amygdala: Their depletion in Alzheimer's disease and morphologic alteration in nondemented elderly with numerous senile plaques. Brain Res 1993;625:125-38
10. Emre M, Heckers S, Mash DC, Geula C, Mesulam MM. Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's disease. J Comparative Neurology 1993;336:117-34
11. Hof PR, Cox K, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex. J Comp Neurol 1990;301:44-54
12. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in AD. Lancet 1976;2:1403
13. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-39
14. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R, Differential alteration of various cholinergic markiers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988;50:1914-23
15. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988;275:216-40
16. Coyle JT, Price DL, Delong MR. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983;219:1184-90
17. Nagai T, McGeer, PL, Peng JH, McGeer EG, Doiman CE. Choline acetyltransferase immunohistochemistry in brains of Alzheimer's disease patients and controls. Neuroscience Letters 1983;36:195-99
18. Hedreen JC, Struble RG, Whitehouse PJ, Price DL. Topography of the magnocellular basal forebrain system in human brain. J Neuropathol Exp Neurol 1984;43:1-21
19. Mesulam MM, Mufson EJ, Levey AL, Wainer BH. Cholinergic innervation of cortex by basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the Rhesus monkey. J Comp Neurol 1983;214:170-97
20. Mesulam MM, Hersh LB, Mash DC, Geula C. Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: A choline acetyltransferase study. J Comp Neurol 1992;318:316-28
21. Pearson RCA, Esiri MM, Hiorns RW, Wlcock GK, Powell TPS. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer's disease. Proceedings of the National Academy of Sciences USA 198;82:4531-34
22. Samuel W, Terry RD, DeTeresa R, Butters N, Masliah E. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch Neurol 1994;51:772-78
23. Davis P, Maloney, AJ. Selective loss of central cholinergic neurons in AD. Lancet 1976;2:1403.
24. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits. J Neurochem 1995;64:749-60
25. Flicker C, Dean RL, Watkins DL, Fisher SK, Bartus RT. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacol Biochem Behav 1983;18:973-81
26. Walsh TJ, Tilson HA, DeHaven DL, Mailman RB, Fisher A, Hanin, I. AF64A, a cholinergic neurotoxin, selectively depletes acetylocholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat. Brain Res 1984;321:91-102
27. Kesner RP, Adelstein T and Crutcher KA. Rats with nucleus basalis magnocellularis lesions mimic mnemonic symptomatology observed in patients with dementia of Alzheimer type. Behavioral Neuroscience 1987;101:451-56.
28. Mallet PE, Beninger RJ, Flesher SN, Jhamandas K, Boegman RJ. Nucleus basalis lesions: Implication of basoamygdaloid cholinergic pathways in memory. Brain Res Bull 1995;36:51-56
29. Bonner TI. Domains of muscarinic acetylcholine receptors that confer specificity of G-protein coupling. Trend Pharmacol Sci 1992;13:48-52
30. Peralta EG, Ashkenazi A, Winslow JW, Ramachandran J, Capon DJ. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature 1988;334:434-37
31. Dörje F, Wess J, Lambrecht G, Tacke R, Mutschier E, Brann MR. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 199156:727-33
32. Andrews JS, Jansen JHM, Linders S, Princen A. Effects of disrupting the cholinergic system on short-term spatial memory in rats. Psychopharm 1994;114:485-94
33. Drachman DA, Leavitt J. Human memory and the cholinergic system: A relationship to aging? Arch Neurol 1974;30:113-21
34. Davis KL, Mohs RC, Tinklenberg JR, et al. Physostigmine: Improvement of long-term memory processes in normal humans. Science 1978:201-74
35. Bymaster FP, Heath I, Hendrix JC, Shannon HE. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 1993;267:16-24
36. Ohno M, Yamamoto T, Watanabe S. Blockade of hippocampal M1 muscarinic receptors impairs working memory performance of rats. Brain Res 1994;650:260-66
37. Ukai M, Shinkai N, Tsutomu K. Cholinergic receptor agonists inhibit pirenzepine-induced dysfunction of spontaneous alternation performance in the mouse. General Pharmacol 1995;26:1529-32
38. Jenike H, Albert MS, Heller H, Gunther J, Goff D. Oral physostigmine treatment for patients with persenile and senile dementia of the Alzheimer type: A double-blind placebo controlled trial. J Clin Psychiatry 1990;51:3-7
39. Stern Y, Sano M, Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 1988;38:1837-41
40. Gautheir S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. New England Journal of Medicine 1990;322:1272-76
41. Thai LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Ger Soc 1989;37:42-48
42. Eagger, SA, Levy, R. Sahakian, BJ. Tacrine in Alzheimer's disease. Acta Neurol Scand Suppl 1992;139:75-80
43. Davis RE, Doyle PD, Carroll RT, Emmerling MR, Jaen J. Cholinergic therapies in Alzheimer's disease. Arzneim Forsch/Drug Res 1995;45:425-31
44. Farlow MR, Lahiri DK, Poirer J, Davignon J, Schneider L, Hui SI. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 1998;50:669-77
45. Riekkinen P, Soininen H, Artanen J, Paallonen A, Helisalmi S, Riekkinen P. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients. Psychopharmacology 1997;129:285-88
46. Farlow MR, Lahiri DK, Poirer J, Davignon J, Hui S. Apolipoprotein E genotype and gender indfluence response to tacrine therapy. Ann NY Acad Sci 1996;802:101-10
47. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, McKeith IG, Perry RH. Neocortical cholinergic activities differentiated Lewy body dementia from Alzheimer's disease. Clin Neurosci Neuropath 1994;5:747-49
48. Rogers L, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24 week, double-blind, placebo-controlled trail of donepezil in patients with Alzheimer's disease. Neurology 1988;50:136-45
49. Giacobini, E. From molecular structure to Alzheimer therapy. Eur J Pharmacol 1997;74:225-41
50. Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 1980;283:90-92
51. Tariot, PN, Cohen, RM, Welkowitz, JA, Sunderland, T, Newhouse, PA, Murphy, DL, Weingartner, H. Multiple dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 1988;45:901-5
52. Penn, RD, Martin, EM, Wilson, RS, Fox, JH, Savoy, SM. Intraventricular bethanechol infusion for Alzheimer's disease: Results of double-blind and escalating dose trials. Neurology 1988;38: 219-22
53. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;54:465-73
54. Growdon JH. Muscarinic agonists in Alzheimer's disease. Life Sci 1997:60:993-38
55. Huang X, Morielli AD, Peralta EG. Tyrosine kinase-dependent suppression of a potassium channel by the G protein-coupled m1 muscarinic acetylcholine receptor. Cell 1993;75:1145-56
56. Caulifield MP, Jones S, Vallis Y, Buckley NJ, Kim GD, Milligan G, Brown DA. Muscarinic M-current inhibition via Gαq/11 and α-adrenocepter inhibition of Ca2+current via Gαo in rat sympathetic neurones. J Physiol 1994;477:415-22
57. +-channel in a vertebrate neuron. Nature 1980;283: 673-76
58. Cole AE, Nicoll RA. Characterization of a slow cholinergic post-synaptic potential recorded from rat hipppocampal pyramidal cells. J Physiol 1984;352:173-88
59. Hille B. G protein-coupled mechanisms and nervous signaling. Neuron 1992;9:187-95
60. Brown DA. Slow cholinergic excitation-A mechanism for increasing neuronal excitability. Trend Neurosci 1983;6:302-7
61. Swanson LW, Teyler TJ, Thompson RF. Hippocampal long-term potentiation: Mechanisms and implications for memory. Neurosci Res Bull 1982;20:613-79
62. Maeda T, Kaneko S, Satoh M. Bidirectional modulation of long-term potentiation by carbachol via M1 and M2 muscarinic receptors in guinea pig hippocampal mossy fiber-CA3 synapses. Brain Res 1993;619:324-30
63. Jacobsen JS, Spruyt MA, Brown AM, et al. The release of Alzheimer's disease β amyloid peptide is reduced by phorbol treatment. J Biol Chem 1994;269:8376-82
64. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-7
65. Master CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:82:4245-49
66. Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 1992;255:728-30
67. Haas C, Schlossmacher MG, Hung AY, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322-25
68. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992;258:126-29
69. Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: Their nature and pathogenesis. Appl Pathol 1984;2:357-69
70. Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P. Processing of Alzheimer βA4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation. Proceedings of the National Academy of Sciences USA 1990;87:6003-6
71. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995;6: 633-36
72. Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, Growdon JH, Selkoe DJ. Activation of protein kinase C inhibits cellular production of the amyloid β-protein. J Biol Chem 1993;268:22959-62
73. Nitsch RM, Slack BE, Farber SA, et al. Receptor-coupled amyloid precursor protein processing. Ann NY Acad Sci 1993;695:122-27
74. Lee RKK, Wurtman RJ, Cox AJ, Nitsch RM. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proceedings of the National Academy of Sciences USA 1995;92:8083-87
75. Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 1996;271:4188-94
76. Slack BE, Breu J, Petryniak MA, Srivastava K, Wurtman RJ. Tyrosine phosphorylation-dependent stimulation of amyloid precursor protein secretion by the m3 muscarinic acetylcholine receptor. J Biol Chem 1995;270:8337-44.
77. Desdouits F, Buxbaum JD, Desdouits-Magnen J, Nairn AC, Greengard P Amyloid β peptide formation in cell-free preparations. J Biol Chem 1996;271:24670-74
78. Qian N, Russell M, Johnson GL. Acetylcholine muscarinic receptor regulation of the Ras/Raf/MAP kinase pathway. Life Sciences 1995;56:945-49
79. Baumann K, Mandelkow E-M, Biernat J, Piwnica-Worms H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS 1993;336: 417-24
80. Paudel HK, Lew J, Zenobia A, Wang JH. Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J Biol Chem 1993;268:23512-18
81. Singh TJ, Haque N, Grundke-Iqbal I, Iqbal K. Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Letters 1995;358:267-72
82. Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates the tau phoshorylation in transfected PC12 cells. J Neurochem 1996;66: 877-80
83. Mangels LA, Gnegy ME. Carbachol stimulates binding of a photoreactive calmodulin derivative to calmodulin-binding proteins in intact SK-N-SH human neuroblastoma cells. J Biol Chem 1992;267:5847-54
84. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R. Comparative alterations of nicotinic and muscarinic receptor binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 1992;58:529
85. Flynn DD, Mash DC. Characterization of L-[3H]nicotine binding in human cerebral cortex: Comparison between Alzheimer's disease and the normal. J Neurochem 1986;47:1948
86. Nordberg A, Winblad B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer's brains. Neurosci Lett 1986;72:115-19
87. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985;228:1115-17
88. Flynn DD, Weinstein DA, Mash DC. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies. Ann Neurol 1991;29:256-62
89. Potter LT, Ferrendelli CA. Affinities of different cholinergic agonists for the high and low affinity states of hippocampal muscarinic receptors. J Pharmacol Exp Ther 1989;248:974-78
90. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987;237:527-32
91. q/11 and phospholipase C-β1. J Biol Chem 1992;267:8081-88
92. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activatibn of protein kinase C. Science 1992;258:607-14
93. Iqbal K, Alonso AC, Gong CX, Khatoon S, Singh TJ, Grundke-Iqbal I. Mechanism of neurofibrillary degeneration in Alzheimer's disease. Mol Neurobiol 1994;9:119-23
94. Birdsall NJM, Burgen SV, Hulme EC. The binding of agonists to brain muscarinic receptors. Mol Pharmacol 1978;14:723-36
95. Smith J, Perry EK, Perry RH, Fairbairn AF, Birdsall NJM. Guanine nucleotide modulation of muscarinic cholinergic receptor binding in postmortem human brain-A preliminary study in Alzheimer's disease. Neuroscience Letters 1987;82:227-32
96. 2 hydrolysis in Alzheimer's disease. Life Sciences 1993;53:439-44
97. Jope RS, Song L, Li X, Powers R. Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiol Aging 1994;15:221-26
98. Jope RS, Song L, Powers RE. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Neurobiol Aging 1997;18:111-20
99. Kelly JF, Furukawa K, Barger S, et al. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proceedings of the National Academy of Sciences USA 1996;93:6753-58
100. Scinto LF, Daffner KR, Dressler D, Ransil BI, Rentz D, Weintraub S, Mesulam M, Potter H. A potential noninvasive neurobiological test for Alzheimer's disease. Science 1994;266:1051-54
101. 3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. J Pharmacol Exp Therap 1984;228:648-55
102. FitzSimon JS, Waring SC, Kokmen E, McLaren JW, Brubaker RF. Response of the pupil to tropicamide is not a reliable test for Alzheimer's disease. Arch Neurol 1997;54:155-59
103. Loupe DN, Newman NJ, Green RC, Lynn MJ, Williams KK, Geis TC, Edelhauser HF. Pupillary response to tropicamide in patients with Alzheimer's disease. Opthalmology 1996;103:495-503
104. Arai H, Terajima M, Nakagawa T, Higuchi S, Mochizuki H, Sasaki H. Pupil dilation assay by tropicamide is modulated by apolipoprotein E epsilon 4 allele dosage in Alzheimer's disease. Neuroreport 1996;7:918-20
105. Medina A, Bodick N, Goldberger AL, MacMahon M, Lipsitz LA. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension 1997;29:828-34
106. Warpman U, Alafuzoff I, Nordberg A. Coupling of muscarinic receptors to GTP proteins in postmortem human brain - alterations in Alzheimer's disease. Neuroscience Letters 1993;150:39-43
107. Ladner CJ, Celesia GG, Magnuson DJ, Lee JM. Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. J Neuropathol Exp Neurol 1995;54:783-89
108. Hosey M. Diversity of structure, signaling and regulation within the family of muscarinic receptors. FASEB 1992;6:854-52
109. Lefkowitz RJ, Hausdorff WP, Caron MG. Role of phosphorylation in desensitization of the β-adrenoreceptor. Trend Pharmacol Sci 1990;11:190-94
110. Haga K, Kameyama K, Haga T, Kikkawa U, Shiozaki K, Uchiyama H. Phosphorylation of human m1 muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 and protein kinase C. J Biol Chem 1996;271:2776-82
111. Haga T, Haga K, Kameyama K, Nakata H. Phosphorylation of muscarinic receptors: regulation by G proteins. Life Sciences 1993;52:421-28
112. Ho AKS, Ling Q-L, Duffield R, Lam PH, Wang JH. Phosphorylation of brain muscarinic receptor: Evidence of receptor phosphorylation. Biochemical Biophys Res Commun 1987;142:9111-18
113. Ho AKS, Wang JH. Calmodulin regulation of cholinergic muscarinic receptor: Effects of calcium and phosphorylating states. Biochem Biophys Res Comm 1985;133:193-1200
114. Sakuta H, Sekiguchi M, Okamoto K, Sakai Y. Oscillatory muscarinic acetylcholine responses of Xenopus oocytes are desensitized by protein kinase C and sensitized by protein phosphatase 2B. Eur J Pharmacol 1991;208:297-305
115. Larsson C, Ailing C. Calmidazolium inhibits muscarinic receptor-mediated PLC activation in SH-SY5Y cells. Neuroreport 1995;6: 1333-37
116. Bahouth SW, Gokmen-Polar Y, Coronel EC, Fain JN. Enhanced desensitization and phosphorylation of the β1-adrenergic receptor in rat adipocytes by peroxovanadate. Mol Pharmacol 1996;49: 1049-57
117. 1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease. Arch Neurol 1990;47:761-3
118. Huang H, Gibson GE. Altered β-adrenergic receptor stimulated cAMP formation in cultured skin fibroblasts from Alzheimer donors. J Biol Chem 1993;268:14616-21
119. Cowburn RF, O'Neill C, Ravid R, Alafuzoff I, Winblad B, Fowler CJ. Adenylyl cyclase activity in postmortem human brain: Evidence of altered G protein mediation in Alzheimer's disease. J Neurochem 1992;58:1409-19
120. 1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease. Neurosci Lett 1991;133;15-19
121. O'Neill C, Fowler C, Wiehager B, Cowburn R, Alafuzoff I, Winblad B. Coupling of human brain cerebral cortical adrenoreceptors to GTP-binding proteins in Alzheimer's disease. Brain Res 1991;563:39-43
122. McLaughlin M, Ross BM, Milligan G, McCulloch J, Knowler JT. Robustness of G proteins in Alzheimer's disease: An immunoblot study. J Neurochemistry 1991:57:9-14